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Summary 35 
Extensively drug-resistant organisms (XDRO) are a global threat to health. Colonisation with XDRO 36 
prior to hematopoietic cell transplantation (HCT) frequently results in delayed delivery of 37 
antimicrobials to which the organisms are susceptible and significantly increases non-relapse 38 
mortality.  Their inherent resistance to available antimicrobial agents coupled with a preponderance 39 
to evolve further resistance makes biological approaches attractive.  Suppression of pathogenic 40 
organisms by fecal microbiome transplantation has previously been demonstrated, and here we 41 
detail use of this approach to successfully supress XDRO prior to HCT that permitted an uneventful 42 
transplant course in an otherwise high-risk situation.  43 
 4 
Non-relapse mortality (NRM) of allogeneic hematopoietic cell transplantation (HCT) has 44 
progressively fallen over the last four decades. Better supportive care, particularly in managing 45 
infection has significantly contributed to the improved safety over that period. However, 46 
antimicrobial resistance poses a significant global threat to health (1), and the emergence of 47 
extensively drug-resistant organisms (XDRO) within HCT units now poses a direct threat to transplant 48 
recipients (2). Gut colonisation with XDRO has been associated with an inased NRM (3) and 49 
infections with XDRO during neutropenic periods are complex to manage and associated with a high 50 
mortality (2). Innovative approaches in preventing and managing them are therefore necessary to 51 
avoid reversing much of the progress made in limiting NRM over the last 4 decades. 52 
A 63-year-old man presented to our institution with a new diagnosis of Philadelphia positive acute 53 
lymphoblastic leukemia and received treatment following the UKALLXII trial schedule (4). He 54 
achieved complete remission after induction chemotherapy together with imatinib. Following 55 
intensification chemotherapy and continuous imatinib, allogeneic HCT was recommended to 56 
consolidate his therapy. His treatment course was complicated by two separate episodes of 57 
extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli bloodstream infections, two 58 
episodes of Clostridium difficile infection (CDI), and central line-related methicillin sensitive 59 
Staphylococcus aureus bacteremia. Each infection was successfully treated with antimicrobials, but 60 
he was subsequently found to be colonised with a highly-resistant ges-5 carbapenemase-producing 61 
Enterobacteriaceae (CPE), Klebsiella oxytoca, on routine rectal screening (table 1). 62 
While gut colonisation with XDRO does not pose any significant risk per se, these organisms can 63 
cause opportunistic infection during periods of prolonged neutropenia. Rates of spontaneous 64 
clearance of these organism from colonised individuals are low, even in immunocompetent hosts, 65 
ranging from 7-30% (5,6). Treatment options for elimination of XDRO from their site of origin within 66 
the intestine are limited; non-absorbable antimicrobial agents often lead to only transient 67 
suppression (5), and may precipitate the development of further resistance. Given the success of 68 
donor fecal microbiota transplant (FMT) in the management of recurrent/refractory CDI (7),  and the 69 
apparently acceptable safety profile when used for CDI in the HCT setting (9), there is considerable 70 
interest in the potential role of FMT in gut decontamination prior to HCT. Recipients of FMT for CDI 71 
have been shown to have fewer antibiotic-resistant organisms within their gut microbiota following 72 
transplantation (10) and there are emerging clinical reports of successful use of FMT in gut 73 
decontamination of a variety of XDRO (including ESBL and CPE) (11), even in the setting of 74 
haematological disorders (8). Therefore after discussion, this patient was offered FMT prior to 75 
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allogeneic HCT in an attempt to eradicate the XDRO and C. difficile from its intestinal niche, with the 76 
aim of minimising his HCT NRM.  77 
Following informed consent, the patient received gut preparation with four days of oral vancomycin 78 
and neomycin, both 500mg four times daily. Antibiotics were stopped 24 hours prior to FMT 79 
delivery, and preparation was completed with iso-osmotic bowel purgatives (Kleen Prep). The 80 
unrelated donor stool was pre-screened, and negative for C. difficile PCR and toxin, as well as for 81 
XDRO; other routine donor screening for transmissible infection was also negative (12). Preparation 82 
of the transplant occurred immediately after stool donation under strict anaerobic conditions, using 83 
an adapted version of a previously-described protocol (13) and stored at -80°C until required. The 84 
FMT product comprised a thawed slurry of around 100ml homogenised stool preserved in a mixture 85 
of glycerol and phosphate buffered saline (15:85, v/v) and was delivered via nasogastric tube. 86 
Fasting was instituted six hours prior to receipt of the FMT, and treatment with a proton-pump 87 
inhibitor (omeprazole) and pro-kinetic (metoclopramide) were administered one hour prior to FMT 88 
delivery.  The patient was allowed to eat and drink normally one-hour post-administration. Following 89 
the procedure, he experienced mild nausea, loose stool and abdominal discomfort, which all 90 
resolved after 24 hours without any specific intervention. Repeat rectal screening 7 days following 91 
the FMT showed continued carriage of the ESBL E. coli but no evidence of ges-5 K. oxytoca CPE or C. 92 
difficile. By day 16 after FMT neither the CPE nor ESBL were detected on rectal screening swabs 93 
(Table 1). 94 
Two weeks after FMT, the patient underwent a fludarabine (30mg/m2 D-7 to -3) and melphalan 95 
(140mg/m2 day -2) conditioned reduced intensity sibling allogeneic HCT, with standard cyclosporine 96 
and methotrexate graft-versus-host disease (GvHD) prophylaxis. The transplant course was 97 
complicated by one episode of neutropenic fevers on day +5, with isolation of a fully-sensitive 98 
Enterococcus faecalis from blood cultures (table 1). Empirical treatment with piperacillin-tazobactam 99 
(4.5g three times daily), amikacin (15mg/kg once daily), teicoplanin (12mg/kg twice daily for three 100 
doses, followed by 12mg/kg once daily) as per local policy with addition of colistin (3 million units 101 
twice daily) resulted in prompt resolution of fever within 24 hours, and following isolation of the 102 
sensitive organism antimicrobials were de-escalated to piperacillin-tazobactram and teicoplanin. A 103 
second episode of neutropenic fever developed on day +10, and responded to a change in 104 
antimicrobials from piperacillin-tazobactam to meropenem (1g three times daily), and cultures 105 
remained sterile. Neutrophil engraftment was achieved on day +25 and the patient was discharged 106 
from hospital on day +29.  At day +100 he was well, with no evidence of leukemia, GvHD or XDRO by 107 
rectal screening.  At 12-months post-transplant the patient remains well and in remission.  108 
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Carbapenemase-producing micro-organisms are now endemic in a number of countries (1,14) and 109 
the preponderance of these organism to extend their resistance spectrums is now contributing to 110 
the emergence of strains resistance to our last resorts antimicrobials (15). A paucity in novel 111 
antimicrobials means that current approaches are restricted to minimising the risk of XDRO 112 
colonisation by antimicrobial stewardship and infection control, as well as managing clinical infection 113 
with complex, and often more toxic, antimicrobial schedules. Novel strategies are therefore 114 
required, and biological approaches would seem most favourable given the weaknesses of our 115 
current pharmacological armoury. Resident gut commensals are adapted to the intestinal 116 
microenvironment and have developed complex ecological networks upon which they have 117 
subsequently become interdependent. Pathogens are equally reliant on their microenvironment, 118 
and competition for critical nutrients, alteration of pH or oxygen tension, and production of toxic 119 
metabolites are all mechanisms by which healthy commensals are capable of supressing pathogens 120 
(16). While FMT has been reported in decontamination of XDRO in immunocompromised (17) 121 
patients and those with blood disorders before (8) here we detail our use of this biological approach 122 
in the suppression of XDROs in order to minimise NRM prior to allogeneic HCT. Our experience 123 
supports the use of FMT in this setting as safe and tolerable, and warrants further study of efficacy in 124 
a randomised fashion. The suppression of XDRO by FMT pre-HCT is particularly pertinent because 125 
rather than simply identifying an addition risk factor for NRM, the presence of XDROs should been 126 
considered a potentially modifiable risk factor, and this distinction is exceptionally important in risk 127 
stratification. 128 
 129 
  130 
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Legend 131 
Table 1. Microbiological sample results/Timeline. E.Coli, Escherichia coli, K. Oxytoca, Klebsiella 132 
Oxytoca, S. aureus, staphylococcus aureus, E. Faecalis, Enterococcus faecalis, R, resistant, S, 133 
susceptible, I, intermediate, C. difficle, Clostridium difficle, PCR, Polymerase chain reaction, HCT, 134 
hematopoietic cell transplantation, XRDO, extensively drug-resistant organism. 135 
  136 
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